• Company
• New HCV drug Epclusa lands in hospitals with reimb
• by Eo, Yun-Ho Dec 22, 2022 05:52am

• Company
• Dong-A ST introduces candidate substance technology
• by Kim, Jin-Gu Dec 22, 2022 05:52am

• Product
• Get rid of Imotun & Godex which waste taxpayers' money
• by Dec 22, 2022 05:52am

• Policy
• New reimbursement standards set for Kymriah·Zolgensma
• by Kim, Jung-Ju Dec 22, 2022 05:52am

• Company
• PO SMA tx Indication of Evrysdi expands
• by Eo, Yun-Ho Dec 21, 2022 06:05am

• Policy
• Lucentis biosimilar enters KRW 35B market in Korea
• by Lee, Tak-Sun Dec 21, 2022 06:05am

• Policy
• Shingrix will be released as a national lot on the 16th
• by Lee, Tak-Sun Dec 21, 2022 06:05am

• Opinion
• [Reporter’s View] Preserve the industry's willpower
• by Dec 21, 2022 06:05am

• Company
• Organon sold 3 types of infertility & contraceptives
• by Dec 21, 2022 06:05am

• Company
• Verzenio attempts reimb in early breast cancer in Korea
• by Eo, Yun-Ho Dec 20, 2022 06:06am